Are Peptides Like BPC-157 Safe? Drug Researcher Leigh Baxt Explains | Dr Leigh Baxt

About this video

• Video Title: Are Peptides Like BPC-157 Safe? Drug Researcher Leigh Baxt Explains | Dr Leigh Baxt
• Channel: The Proof with Simon Hill
• Speakers: Leigh Baxt, Simon Hill
• Duration: 00:10:43

Overview

This video features a discussion between Simon Hill and drug researcher Leigh Baxt about the safety and regulation of peptides, particularly those marketed for wellness. Baxt clarifies her expertise, differentiating between small molecules, biologics, and peptides, and outlines the rigorous drug development process required for FDA approval. The conversation highlights the risks associated with "research use only" peptides, which often lack sufficient human data and regulatory oversight, contrasting them with approved peptide medications like GLP-1 agonists and insulin.

Key takeaways

• Leigh Baxt's expertise lies primarily in small molecules and biologics, with peptides occupying a unique space between these two categories.
• The process for drug approval is extensive, typically taking 10-15 years, involving multiple stages of research, pre-clinical development, and human clinical trials (Phases 1, 2, and 3).
• Many compounds, even those showing promise in early research, fail during the drug development process due to various reasons, including biological hypotheses not holding up or poor translation from animal models to humans.
• Peptides sold for "research use only" in the wellness community often lack sufficient human data and have not undergone the rigorous drug development and regulatory processes, making their safety and efficacy for human consumption uncertain.
• The marketing of these unapproved peptides can be misleading, preying on individuals seeking solutions for health concerns, and carries significant risks due to the unknown effects and potential for impurities.